Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-09-26
1999-01-26
Chambers, Jasemine C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4351723, 435 691, 435375, A61K 4800, C12N 1579
Patent
active
058639047
ABSTRACT:
The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G.sub.0 /G.sub.1, alteration in morphology, and cell differentiation.
REFERENCES:
Marshal, Science, 269: 1050-1055, 1995.
Miller et al., FASEB J., 9: 190-199, 1995.
Culver et al., TIG, 10(5), 174-178, 1994.
Hodgson, Exp. Opin. Ther. Pat., 5(5): 459-468, 1995.
Lafont et al., Lancet, 346: 1442-1443, 1995.
Etienne-Julan et al, The effieciency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker, Journal of General Virology 73: 3251-3255, 1992.
Jolly, Viral vector systems for gene therapy, Cancer Gene therapy, 1:1,51-64, 1994.
Zakut et al, The tumor suppression function of p21 Waf is contained in its N-terminal half, Oncogene, 11:393-395, Jul. 1995.
Indolfi et al, Inhibition of cellular ras prevents smooth muslce cell proliferation after vascular injury in vivo, Nature Medicine, 1:(6) 541-5, Jun. 1995.
Nature, vol. 374, Mar. 23,1995, pp. 386-388, Junjie Chen, et al., "Separate Domains of p21 Involved in the Inhibition of CDK Kinase and PCNA".
Genes & Development, vol. 8, pp. 2540-2551, 1994, Aldo Di Leonardo, et al., "DNA Damage Triggers a Prolonged P53-Dependent G1 Arrest and Long-Term Induction of CIP1 in Normal Human Fibroblasts".
Cancer Research, vol. 54, pp. 1169-1174, Mar. 1, 1994, Wafik S. El-Deiry, et al., "WAF1/CIP1 is Induced in P53-Mediated G1 Arrest and Apoptosis".
Cell, vol. 75, pp. 817-825, Nov. 19, 1993, Wafik S. El-Deiry, et al., "WAF1, A Potential Mediator of P53 Tumor Suppression".
Nature, vol. 366, Dec. 16, 1993, pp. 707-710, Yong Gu, et al., "Inhibition of CDK2 Activity In Vivo by an Associated 20K Regulatory Subunit".
Cell, vol. 75, pp. 805-816, Nov. 19, 1993, J. Wade Harper, et al., "The P21 CDK-Interacting Protein CIP1 is a Potent Inhibitor of G1 Cyclin-Dependent Kinases".
Nature, vol. 371, Oct. 6, 1994, pp. 534-537, Rong Li, et al., "Differential Effects by the P21 CDK Inhibitor on PCNA-Dependent DNA Replication and Repair".
Oncogene, vol. 9, 1994, pp. 2261-2268, Yan Li, et al., "Cell Cycle Expression and P53 Regulation of the Cyclin-Dependent Kinase Inhibitor P21".
Nature, vol. 369, Jun. 16, 1994, pp. 574-578, Shou Waga, et al., "The P21 Inhibitor of Cyclin-Dependent Kinases Controls DNA Replication by Interaction with PCNA".
Nature, vol. 366, Dec. 16, 1993, pp. 701-704, Yue Xiong, et al., "P21 is a Universal Inhibitor of Cyclin Kinases".
Genes & Development, vol. 8, pp. 1750-1758, 1994, Hui Zhang, et al., "P21-containing Cyclin Kinases Exist in Both Active and Inactive States".
Nabel Elizabeth G.
Nabel Gary J.
Yang Zhi-yong
Chambers Jasemine C.
Hauda Karen M.
The University of Michigan
LandOfFree
Methods for treating cancers and restenosis with P21 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating cancers and restenosis with P21, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating cancers and restenosis with P21 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1450540